Dossier assessment
Abemaciclib in combination with an aromatase inhibitor (breast cancer) - Benefit assessment according to §35a Social Code Book V
Report documents
-
Extract of dossier assessment
Abemaciclib in combination with an aromatase inhibitor (breast cancer) - Benefit assessment according to §35a Social Code Book V
-
Dossier assessment
Abemaciclib in combination with an aromatase inhibitor (breast cancer) - Benefit assessment according to §35a Social Code Book V
Dossier assessment
Women with HR-positive, HER2-negative locally advanced or metastatic breast cancer
Initial endocrine therapy in postmenopausal women: indication of lesser benefit in comparison with appropriate comparator therapy. Subsequent endocrine therapy and/or pre- or perimenopausal women: added benefit not proven due to a lack of study data.
Additional information
Federal Joint Committee (G-BA)
2019-05-02 A G-BA decision was published.
Project details
- Project no.
- A18-72
- Commission
- Commission awarded on 29.10.2018 by the Federal Joint Committee (GBA).
- Report type
- Dossier assessment
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Cancer
- Note
-
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
Connected Projects
-
Dossier assessment
Abemaciclib (breast cancer; combination with fulvestrant) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Addendum
Abemaciclib (breast cancer; combination with an aromatase inhibitor) - Addendum to Commission A18-72
Status: Commission completed
-
Dossier assessment
Abemaciclib in combination with fulvestrant (breast cancer) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Abemaciclib (breast cancer; adjuvant treatment) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Abemaciclib (breast cancer; combination with an aromatase inhibitor) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Abemaciclib (breast cancer) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Abemaciclib (breast cancer; combination with fulvestrant) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed